Detalhe da pesquisa
1.
Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis.
N Engl J Med
; 385(24): 2219-2229, 2021 12 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34879448
2.
Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis.
J Am Acad Dermatol
; 84(3): 632-638, 2021 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-32502588
3.
Clinical and Molecular Effects of Interleukin-17 Pathway Blockade in Psoriasis
J Drugs Dermatol
; 19(2): 138-143, 2020 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32129957
4.
Executive Summary: From the Medical Board of the National Psoriasis Foundation: Perioperative management of immunomodulatory agents in patients with psoriasis and psoriatic arthritis.
J Am Acad Dermatol
; 2024 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-38499181
5.
Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10.
J Immunol
; 198(10): 3809-3814, 2017 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28389592
6.
Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.
BMC Dermatol
; 16(1): 15, 2016 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27716172
7.
Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials.
Acta Derm Venereol
; 99(9): 820-821, 2019 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31017248
8.
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials.
J Dermatolog Treat
; 35(1): 2329240, 2024 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38679419
9.
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
Am J Clin Dermatol
; 25(2): 299-314, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38263353
10.
Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere).
JAMA Dermatol
; 159(2): 182-191, 2023 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630140
11.
Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study.
J Dermatol Sci
; 109(1): 12-21, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36690571
12.
Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study.
Dermatol Ther (Heidelb)
; 13(7): 1517-1534, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-37318750
13.
Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials.
J Dermatolog Treat
; 33(1): 261-265, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32250714
14.
Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy.
J Dermatolog Treat
; 33(4): 2057-2062, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-34176407
15.
Similar efficacy, safety, and immunogenicity of the biosimilar BI 695501 and adalimumab reference product in patients with moderate-to-severe chronic plaque psoriasis: results from the randomized Phase III VOLTAIRE-PSO study.
Expert Opin Biol Ther
; 21(1): 87-96, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33317345
16.
Association of Secukinumab Treatment With Tuberculosis Reactivation in Patients With Psoriasis, Psoriatic Arthritis, or Ankylosing Spondylitis.
JAMA Dermatol
; 157(1): 43-51, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33001147
17.
Treating moderate plaque psoriasis: prospective 6-month chart review of patients treated with apremilast.
J Dermatolog Treat
; 30(5): 430-434, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-30339049
18.
Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.
Cutis
; 103(2): 111-116, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30893392
19.
A single-center, double-blind, randomized trial of the atrophogenic effects of fluocinonide cream 0.1% versus clobetasol propionate cream 0.05% in participants with corticosteroid-responsive dermatoses.
Cutis
; 81(6): 517-9, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18666395
20.
Defining and treating moderate plaque psoriasis: a dermatologist survey.
J Dermatolog Treat
; 29(7): 658-663, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-29502473